Loading…

Synthesis of trimetallic iron-boron core and gold shell nanoparticles for experimental cancer radiotherapy

Cancer is a significant and constantly growing clinical problem all over the word. For many types of cancer there has been little change in mortality rate of CRC in the past decades and treatment options are limited. A striking example is malignant Glioblastoma (GBM) which exhibits a high degree of...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in bioengineering and biotechnology 2024-09, Vol.12, p.1448081
Main Authors: Coward, Brad, Wang, Jiawei, Kysela, Boris
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c350t-25473d557d15af65ea6889f7a2d1b318fb7ae5280d146df440408aa6e8f2da1d3
container_end_page
container_issue
container_start_page 1448081
container_title Frontiers in bioengineering and biotechnology
container_volume 12
creator Coward, Brad
Wang, Jiawei
Kysela, Boris
description Cancer is a significant and constantly growing clinical problem all over the word. For many types of cancer there has been little change in mortality rate of CRC in the past decades and treatment options are limited. A striking example is malignant Glioblastoma (GBM) which exhibits a high degree of infiltration of surrounding healthy brain tissue, extremely high mortality rate, morbidity and most life-years lost of any cancer. Considerable research efforts in the last several decades have failed to improve these outcomes. Boron Capture Neutron Therapy (BNCT) is an experimental radiotherapy (RT) that shows the best hope for the patients for whom all current therapies fail. BNCT involves the intracellular release of alpha and Li-ion particles from boron in response to neutron beam and therefore its success is critically dependent on achieving high intracellular concentrations of boron atoms within the cancerous cells. Boron phenylalanine (BPA) is the most used compound to deliver boron atoms, but achieving high intracellular concentration of BPA is difficult with this small molecule compound and is an absolute limiting factor for the better outcome of BNCT. Our approach focused on a delivery of a high and stable concentration of boron atoms in a form of novel trimetallic core-shell nanoparticles, combining boron for BNCT and iron for magnetic targeting in the core, and a gold shell for stability and attachment of targeting therapeutic peptides. The research was targeted towards comparing different synthesis variables to form these core-shell particles and incorporate as much boron into the core as possible via redox-transmetalation. Partial gold shells were formed around the core via island growth with a molar ratio of Fe/B of 0.64 and high incorporation of boron.
doi_str_mv 10.3389/fbioe.2024.1448081
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_a32e4e8857124526a153f5f7ff603612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a32e4e8857124526a153f5f7ff603612</doaj_id><sourcerecordid>3109976431</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-25473d557d15af65ea6889f7a2d1b318fb7ae5280d146df440408aa6e8f2da1d3</originalsourceid><addsrcrecordid>eNpVkUtvEzEUhUcIRKvSP8ACeclmgt_2rBCqeFSq1EVhbd2xrxNHk_FgTxD590yaULUb2_K95_O5Pk3zntGVELb7FPuUccUplysmpaWWvWouOe90K5lVr5-dL5rrWreUUsaVUZa_bS5EJ7gwWlw224fDOG-wpkpyJHNJO5xhGJInqeSx7fOyEp8LEhgDWechkLrBYSAjjHmCMic_YCUxF4J_JzzqxwVAPIweCykQUl74BabDu-ZNhKHi9Xm_an59-_rz5kd7d__99ubLXeuFonPLlTQiKGUCUxC1QtDWdtEAD6wXzMbeACpuaWBShyglldQCaLSRB2BBXDW3J27IsHXTYgnKwWVI7vEil7U7-3YgOEq0VhnGpeIamBJRRROjpkIzvrA-n1jTvt9h8MtwBYYX0JeVMW3cOv9xjEnOqT0SPp4JJf_eY53dLlW__CCMmPfVCUa7zmgp2NLKT62-5FoLxqd3GHXH0N1j6O4YujuHvog-PHf4JPkfsfgH1r2q8g</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3109976431</pqid></control><display><type>article</type><title>Synthesis of trimetallic iron-boron core and gold shell nanoparticles for experimental cancer radiotherapy</title><source>PubMed Central</source><creator>Coward, Brad ; Wang, Jiawei ; Kysela, Boris</creator><creatorcontrib>Coward, Brad ; Wang, Jiawei ; Kysela, Boris</creatorcontrib><description>Cancer is a significant and constantly growing clinical problem all over the word. For many types of cancer there has been little change in mortality rate of CRC in the past decades and treatment options are limited. A striking example is malignant Glioblastoma (GBM) which exhibits a high degree of infiltration of surrounding healthy brain tissue, extremely high mortality rate, morbidity and most life-years lost of any cancer. Considerable research efforts in the last several decades have failed to improve these outcomes. Boron Capture Neutron Therapy (BNCT) is an experimental radiotherapy (RT) that shows the best hope for the patients for whom all current therapies fail. BNCT involves the intracellular release of alpha and Li-ion particles from boron in response to neutron beam and therefore its success is critically dependent on achieving high intracellular concentrations of boron atoms within the cancerous cells. Boron phenylalanine (BPA) is the most used compound to deliver boron atoms, but achieving high intracellular concentration of BPA is difficult with this small molecule compound and is an absolute limiting factor for the better outcome of BNCT. Our approach focused on a delivery of a high and stable concentration of boron atoms in a form of novel trimetallic core-shell nanoparticles, combining boron for BNCT and iron for magnetic targeting in the core, and a gold shell for stability and attachment of targeting therapeutic peptides. The research was targeted towards comparing different synthesis variables to form these core-shell particles and incorporate as much boron into the core as possible via redox-transmetalation. Partial gold shells were formed around the core via island growth with a molar ratio of Fe/B of 0.64 and high incorporation of boron.</description><identifier>ISSN: 2296-4185</identifier><identifier>EISSN: 2296-4185</identifier><identifier>DOI: 10.3389/fbioe.2024.1448081</identifier><identifier>PMID: 39323763</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Bioengineering and Biotechnology ; core-shell ; nanoparticle ; nanotherapeutics ; non-aqueous ; redox-transmetalation ; trimetallic</subject><ispartof>Frontiers in bioengineering and biotechnology, 2024-09, Vol.12, p.1448081</ispartof><rights>Copyright © 2024 Coward, Wang and Kysela.</rights><rights>Copyright © 2024 Coward, Wang and Kysela. 2024 Coward, Wang and Kysela</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c350t-25473d557d15af65ea6889f7a2d1b318fb7ae5280d146df440408aa6e8f2da1d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11422082/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11422082/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39323763$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Coward, Brad</creatorcontrib><creatorcontrib>Wang, Jiawei</creatorcontrib><creatorcontrib>Kysela, Boris</creatorcontrib><title>Synthesis of trimetallic iron-boron core and gold shell nanoparticles for experimental cancer radiotherapy</title><title>Frontiers in bioengineering and biotechnology</title><addtitle>Front Bioeng Biotechnol</addtitle><description>Cancer is a significant and constantly growing clinical problem all over the word. For many types of cancer there has been little change in mortality rate of CRC in the past decades and treatment options are limited. A striking example is malignant Glioblastoma (GBM) which exhibits a high degree of infiltration of surrounding healthy brain tissue, extremely high mortality rate, morbidity and most life-years lost of any cancer. Considerable research efforts in the last several decades have failed to improve these outcomes. Boron Capture Neutron Therapy (BNCT) is an experimental radiotherapy (RT) that shows the best hope for the patients for whom all current therapies fail. BNCT involves the intracellular release of alpha and Li-ion particles from boron in response to neutron beam and therefore its success is critically dependent on achieving high intracellular concentrations of boron atoms within the cancerous cells. Boron phenylalanine (BPA) is the most used compound to deliver boron atoms, but achieving high intracellular concentration of BPA is difficult with this small molecule compound and is an absolute limiting factor for the better outcome of BNCT. Our approach focused on a delivery of a high and stable concentration of boron atoms in a form of novel trimetallic core-shell nanoparticles, combining boron for BNCT and iron for magnetic targeting in the core, and a gold shell for stability and attachment of targeting therapeutic peptides. The research was targeted towards comparing different synthesis variables to form these core-shell particles and incorporate as much boron into the core as possible via redox-transmetalation. Partial gold shells were formed around the core via island growth with a molar ratio of Fe/B of 0.64 and high incorporation of boron.</description><subject>Bioengineering and Biotechnology</subject><subject>core-shell</subject><subject>nanoparticle</subject><subject>nanotherapeutics</subject><subject>non-aqueous</subject><subject>redox-transmetalation</subject><subject>trimetallic</subject><issn>2296-4185</issn><issn>2296-4185</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkUtvEzEUhUcIRKvSP8ACeclmgt_2rBCqeFSq1EVhbd2xrxNHk_FgTxD590yaULUb2_K95_O5Pk3zntGVELb7FPuUccUplysmpaWWvWouOe90K5lVr5-dL5rrWreUUsaVUZa_bS5EJ7gwWlw224fDOG-wpkpyJHNJO5xhGJInqeSx7fOyEp8LEhgDWechkLrBYSAjjHmCMic_YCUxF4J_JzzqxwVAPIweCykQUl74BabDu-ZNhKHi9Xm_an59-_rz5kd7d__99ubLXeuFonPLlTQiKGUCUxC1QtDWdtEAD6wXzMbeACpuaWBShyglldQCaLSRB2BBXDW3J27IsHXTYgnKwWVI7vEil7U7-3YgOEq0VhnGpeIamBJRRROjpkIzvrA-n1jTvt9h8MtwBYYX0JeVMW3cOv9xjEnOqT0SPp4JJf_eY53dLlW__CCMmPfVCUa7zmgp2NLKT62-5FoLxqd3GHXH0N1j6O4YujuHvog-PHf4JPkfsfgH1r2q8g</recordid><startdate>20240911</startdate><enddate>20240911</enddate><creator>Coward, Brad</creator><creator>Wang, Jiawei</creator><creator>Kysela, Boris</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240911</creationdate><title>Synthesis of trimetallic iron-boron core and gold shell nanoparticles for experimental cancer radiotherapy</title><author>Coward, Brad ; Wang, Jiawei ; Kysela, Boris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-25473d557d15af65ea6889f7a2d1b318fb7ae5280d146df440408aa6e8f2da1d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Bioengineering and Biotechnology</topic><topic>core-shell</topic><topic>nanoparticle</topic><topic>nanotherapeutics</topic><topic>non-aqueous</topic><topic>redox-transmetalation</topic><topic>trimetallic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Coward, Brad</creatorcontrib><creatorcontrib>Wang, Jiawei</creatorcontrib><creatorcontrib>Kysela, Boris</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in bioengineering and biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coward, Brad</au><au>Wang, Jiawei</au><au>Kysela, Boris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis of trimetallic iron-boron core and gold shell nanoparticles for experimental cancer radiotherapy</atitle><jtitle>Frontiers in bioengineering and biotechnology</jtitle><addtitle>Front Bioeng Biotechnol</addtitle><date>2024-09-11</date><risdate>2024</risdate><volume>12</volume><spage>1448081</spage><pages>1448081-</pages><issn>2296-4185</issn><eissn>2296-4185</eissn><abstract>Cancer is a significant and constantly growing clinical problem all over the word. For many types of cancer there has been little change in mortality rate of CRC in the past decades and treatment options are limited. A striking example is malignant Glioblastoma (GBM) which exhibits a high degree of infiltration of surrounding healthy brain tissue, extremely high mortality rate, morbidity and most life-years lost of any cancer. Considerable research efforts in the last several decades have failed to improve these outcomes. Boron Capture Neutron Therapy (BNCT) is an experimental radiotherapy (RT) that shows the best hope for the patients for whom all current therapies fail. BNCT involves the intracellular release of alpha and Li-ion particles from boron in response to neutron beam and therefore its success is critically dependent on achieving high intracellular concentrations of boron atoms within the cancerous cells. Boron phenylalanine (BPA) is the most used compound to deliver boron atoms, but achieving high intracellular concentration of BPA is difficult with this small molecule compound and is an absolute limiting factor for the better outcome of BNCT. Our approach focused on a delivery of a high and stable concentration of boron atoms in a form of novel trimetallic core-shell nanoparticles, combining boron for BNCT and iron for magnetic targeting in the core, and a gold shell for stability and attachment of targeting therapeutic peptides. The research was targeted towards comparing different synthesis variables to form these core-shell particles and incorporate as much boron into the core as possible via redox-transmetalation. Partial gold shells were formed around the core via island growth with a molar ratio of Fe/B of 0.64 and high incorporation of boron.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>39323763</pmid><doi>10.3389/fbioe.2024.1448081</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2296-4185
ispartof Frontiers in bioengineering and biotechnology, 2024-09, Vol.12, p.1448081
issn 2296-4185
2296-4185
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_a32e4e8857124526a153f5f7ff603612
source PubMed Central
subjects Bioengineering and Biotechnology
core-shell
nanoparticle
nanotherapeutics
non-aqueous
redox-transmetalation
trimetallic
title Synthesis of trimetallic iron-boron core and gold shell nanoparticles for experimental cancer radiotherapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-22T10%3A17%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20of%20trimetallic%20iron-boron%20core%20and%20gold%20shell%20nanoparticles%20for%20experimental%20cancer%20radiotherapy&rft.jtitle=Frontiers%20in%20bioengineering%20and%20biotechnology&rft.au=Coward,%20Brad&rft.date=2024-09-11&rft.volume=12&rft.spage=1448081&rft.pages=1448081-&rft.issn=2296-4185&rft.eissn=2296-4185&rft_id=info:doi/10.3389/fbioe.2024.1448081&rft_dat=%3Cproquest_doaj_%3E3109976431%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c350t-25473d557d15af65ea6889f7a2d1b318fb7ae5280d146df440408aa6e8f2da1d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3109976431&rft_id=info:pmid/39323763&rfr_iscdi=true